Ivermectin, a potential anticancer drug derived from an antiparasitic drug
A 2021 review of the pathways through which ivermectin killed cancer cells in the laboratory, written as a case for testing it in people.
Overview
The review, indexed as a systematic review, collects reports that ivermectin inhibits proliferation of several tumour cell types by regulating multiple signalling pathways and promotes programmed cell death, and discusses prospects for clinical use (Tang review 2021). The evidence it reviews is from cell lines and animal models (Tang review 2021).
- Laboratory mechanisms catalogued: proliferation inhibition and programmed cell death across cancer cell lines.
Useful as a map of the laboratory story; it contains no patient outcomes.
- Preclinical evidence only.
Similar pages
not linked directly; found by shared links- Key paperThe multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
Shares In vitro and in vivo, Systematic drug repurposing, Preclinical, Ivermectin.
- Key paperIvermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)
Shares In vitro and in vivo, Preclinical, Ivermectin.
- TermModel organism
Shares In vitro and in vivo, Preclinical.
- Key paperIvermectin treatment for gynecologic cancers: hope versus hype
Shares Systematic drug repurposing, Ivermectin.
- Key paperIvermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?
Shares Preclinical, Ivermectin.
- TermOrganoid
Shares In vitro and in vivo, Preclinical.
- TermCell line
Shares In vitro and in vivo, Preclinical, Ivermectin.
- TreatmentMebendazole
Shares Systematic drug repurposing, Preclinical, Ivermectin.